Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease
NCT01182584 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2010-12-22
Summary
Graves' disease is characterized by thyrotoxicosis, goiter, ophthalmopathy and dermopathy. Pathogenesis involves autoimmune process. The investigators think temperatures of the area involved in the inflammation may change. Thus the investigators plan to take temperature pictures of Graves' patients using digital infrared thermal imaging system and observe the change.
Conditions
- Graves' Disease
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Shyang-Rong Shih · National Taiwan University
Eligibility
- Min Age
- 16 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2011-10-31
- Completion
- 2011-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Assessment of Thyroid Doppler Ultrasound in Followup of Pediatric Graves' Disease
NCT06357494 ·Status: NOT_YET_RECRUITING
-
Low-dose Radioiodine Ablation in Graves' Disease
NCT03110835 ·Status: COMPLETED
-
Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography
NCT03294005 ·Status: COMPLETED
-
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
NCT07261345 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
T and B Cells in Graves' Orbitopathy
NCT03195296 ·Status: COMPLETED
-
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
NCT03498417 ·Status: COMPLETED
-
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
NCT06590220 ·Status: RECRUITING
-
HIFU vs RAI in the Relapsed Graves' Disease
NCT03013257 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
NCT07152340 ·Status: RECRUITING ·Phase: PHASE4
-
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
NCT02316691 ·Status: TERMINATED
-
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
NCT06443866 ·Status: RECRUITING
-
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306 ·Status: RECRUITING
-
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
NCT02339142 ·Status: UNKNOWN ·Phase: PHASE4
-
Natural History of Thyroid Function Disorders
NCT00001159 ·Status: RECRUITING
-
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
NCT07152392 ·Status: RECRUITING ·Phase: PHASE4
-
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
NCT06268600 ·Status: RECRUITING ·Phase: NA
-
Differentiation of Benign From Malignant Thyroid Nodules Using Diffuse Reflectance Spectroscopy
NCT07124065 ·Status: ACTIVE_NOT_RECRUITING
-
The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
NCT01204359 ·Status: UNKNOWN ·Phase: PHASE3
-
Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis
NCT01129492 ·Status: COMPLETED ·Phase: PHASE2
-
Thyroid Disease and Personality Study
NCT02620085 ·Status: UNKNOWN
-
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
NCT05118542 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818 ·Status: COMPLETED ·Phase: PHASE3
-
Observation in the Treatment of Graves' Disease
NCT05043233 ·Status: UNKNOWN
-
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333 ·Status: COMPLETED ·Phase: PHASE3